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Abstract 
 
Introduction: This paper describes the application and evaluation of a comparative 
urine analysis platform employing reversed-phase liquid chromatography-mass 
spectrometry (LC-MS) and multivariate statistical data analysis for the discovery of 
low-molecular weight (LMW) urinary compounds that are differentially excreted 
in human pregnancy. Methods and materials: Urinary compounds were separated 
by gradient elution and subsequently detected by electrospray ionization (ESI) Ion-
Trap mass spectrometry. Normalization of the injected amount was based on the 
creatinine concentration and on the area under the curve of the UV-chromatogram 
at 214nm (AUC214). Data processing included 2-dimensional smoothing (meshing), 
peak detection with a geometrical algorithm based on local slope, and time 
alignment of the peaks using correlation optimized warping with a two-
dimensional correlation signal based on the peaks themselves. Discriminatory peaks 
were selected from the final peak matrix by supervised classification using the 
nearest shrunken centroid (NSC) algorithm. Final dimensionality reduction and 
visualization were performed using principal component analysis (PCA). Using this 
methodology, urine samples from 7-16 weeks pregnant females (n=25) and age-
matched controls (n=25) were comparatively analyzed. Results: Sample 
classification using all peaks (15876) already showed clear separation of the 
pregnant group from the control group with a sensitivity of 96% and a specificity of 
100%. At a shrinkage of 3.11 (186 discriminatory peaks) sensitivity and specificity 
were 100%. When increasing the shrinkage further to 7.52 (10 discriminatory 
peaks) and to 12.55 (1 discriminatory peak), the sensitivity decreased from 96% to 
92%, respectively, while the specificity remained 100%. Deconvolution of multiple 
charge states and isotopic distributions of the 186 discriminatory peaks resulted in a 
list of 38 discriminatory peaks that also contained the discriminatory peaks from 
higher shrinkage values. Discussion: The current method is capable of 
discriminating urine samples from pregnant and non-pregnant females. 
Optimization of data-processing improved the quality of the selected peaks, 
although a minor number of noisy peaks and redundancy in the peak list of 
discriminatory peaks at low shrinkage values remained. Other classification 
algorithms will be explored as well as improving the currently used NSC, to address 
this problem. Relating sensitivity and specificity to shrinkage value can assist in 
determining the most discriminatory biomarker candidates. Efforts are presently 
directed at identifying discriminatory compounds and at validating the 
classification model in an independent test-set. 
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1. Introduction 
At least some of the pathological changes in human organs are reflected in urine. 
Thus urine-analysis can aid in diagnosis, treatment monitoring and prognosis of 
notably diseases of the genitourinary tract [1]. Biomarker discovery studies have 
used urine as sample matrix, because it can be obtained in large quantities by non-
invasive sampling, it is less complex than blood, and urinary peptides/proteins tend 
to be relatively small in size, water-soluble and rather stable. Compounds in urine 
show furthermore fewer intermolecular interactions than blood compounds [2], 
making their separation, and thus detection and quantification, more easy. 
However, the composition of urine varies greatly between and within individuals 
because of differences in age and gender [3] as well as factors of cultural and dietary 
nature [4]. If possible, these factors should be controlled for by careful matching of 
patients and controls. Recent reviews emphasize important aspects regarding 
urinary biomarker discovery studies and achievements [5;6]. A recent viewpoint 
paper defines some essential factors that should be considered in the design and 
execution of biomarker discovery studies including study group selection, sample 
collection, choice of technology and quality control [7]. This requires close 
interdisciplinary collaboration. 
 Compositional analysis of urine can be done using numerous analytical 
techniques [8] (e.g. 2D gel electrophoresis, separation techniques hyphenated to 
mass spectrometry (MS) and their off-line variants. Liquid chromatography (LC) 
coupled to MS using electrospray ionization (ESI) is a frequently used analytical 
technique to profile urinary compounds for biomarker research, which has the 
advantages of automation, high sensitivity, high resolution and the feasibility of 
detecting thermolabile, water-soluble compounds without the need for chemical 
derivatization. LC-MS is, however, time-consuming and suffers from ion-
suppression effects of interfering compounds. Urine analysis by LC-MS has been 
applied in many fields: peptidomics [9-19], proteomics [1;20-26], metabolomics [27-
29] as well as in drug metabolism research. The use of internal standards and/or 
standardization of the injected amount is necessary in order to correct for possible 
interferences of matrix components with the ionization of compounds of interest in 
quantitative studies to generate comparable LC-MS data [30]. A quantitative label-
free profiling method of complex biological samples seems feasible as long as there 
is linearity of signal versus concentration and a high degree of reproducibility of 
sample processing (i.e. pre-analytical phase) and the LC-MS method (i.e. analytical 
phase) itself [31;32]. 
 In a previous paper [33] we have described the development, evaluation and 
application of a comparative urine analysis platform for the discovery of low-
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molecular weight (LMW) urinary biomarkers using LC-MS and multivariate 
statistical data analysis. We observed that normalization of the injected amount to 
the area under the curve (AUC) of the chromatogram at 214 nm (AUC214) instead of 
creatinine levels was better adapted to the profiling of a wide range of molecules 
with different physico-chemical properties (e.g. molecular weight, pKa, 
hydrophobicity), which was reflected in the lower relative standard deviation 
(RSD) of individual peaks and the total chromatographic peak area. Processing of 
LC-MS data prior to multivariate statistical analysis was implemented in the 
workflow, because this is critical when comparing LC-MS data sets that may reach 
107 to 108 data points per analysis. Data processing has the goal to correct for 
unwanted variations (analytical noise) in data sets [34-36], thus generating a peak 
matrix that contains only relevant information that is comparable. This peak matrix 
is obtained by matching common peaks in different samples and by filling locations 
that ‘miss’ peaks with background subtracted local data. After data processing the 
nearest shrunken centroid (NSC) classification algorithm [37] is used to reduce the 
dimensionality and to select discriminatory peaks. Visual inspection of patterns in 
the high-dimensional data space was done using principal component analysis 
(PCA), a technique that further reduces dimensionality to two dimensions [38]. 
Using this methodology we were able to extract discriminatory peaks from the LC-
MS data of spiking-experiments despite biological and analytical variation down to 
the low nM concentration range. The methodology was applied to identify 
differences in the urinary composition of patients with kidney disease that is 
accompanied by normal protein excretion or proteinuria. This resulted in the 
identification of differentially excreted albumin-derived peptides amongst other 
compounds that allowed discrimination. 
 In this paper we describe the application and evaluation of this comparative 
urine analysis platform for the discovery of LMW biomarkers that are differentially 
excreted in urine from pregnant as compared to non-pregnant females. The 
methodology was improved with respect to data processing and data analysis 
compared to our previous work [33]. The discriminatory peaks that were selected 
by the classification model were evaluated for their discriminatory properties in 
terms of sensitivity and specificity. 
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2. Experimental 
2.1. Subjects: pregnant and non-pregnant females 
Urine samples from 25 pregnant females [median (range) age 38.7 years (29.2-41.3)] 
were retrieved from a biobank of frozen (-20 °C) urine samples from the 
department of Obstetrics and Gynecology of the University Medical Center in 
Groningen (The Netherlands). Urine samples in this biobank originated from 
pregnant females that attended the clinic for prenatal screening because of their 
age. The median (range) duration of gestation of the 25 pregnant females was 9.8 
weeks (7.6-15.7). Samples of first-void midstream morning urines that were 
brought to the hospital, were aliquoted and stored at -20 °C for a median (range) 
period of 7.1 years (7.1-7.2) before analysis by LC-MS. We prospectively collected 
first-void midstream morning urine samples from 25 non-pregnant females [median 
(range) age 27.4 years (21.0-45.5)], notably colleagues and friends. The median 
(range) storage time at -20 °C for the samples from non-pregnant females was 11 
days (3-30) before analysis by LC-MS. 
 Pregnancy was established by measurement of urinary free beta subunits of the 
human chorionic gonadotropin (β-hCG). Urine samples of 25 pregnant females had 
a median (range) β-hCG of 16396 mIU/mL (2713-62103). For 24 controls β-hCG 
levels were below the lower detection limit of 1.2 mIU/mL with one non-pregnant 
control showing a β-hCG level of 22 mIU/mL, because she gave birth 18 days before 
the date of urine collection. All samples were collected in polypropylene containers 
(Sarstedt, Nümbrecht, Germany) and kept at 4 °C for a maximum of 1 day, after 
which they were aliquoted in 10 mL polypropylene tubes (Becton Dickinson, 
Heidelberg, Germany) and stored at -20 °C. None of the subjects was fasting at time 
of urine collection. 
 All subjects that participated in this study gave their oral and/or written 
informed consent. The study protocol was in agreement with local ethical standards 
and the Helsinki declaration of 1964, as revised in 2004. 
2.2. Chemicals 
Acetonitrile (ACN) HPLC-S gradient grade (Biosolve; Valkenswaard, The 
Netherlands), ultra pure water (18.2 MΩ/cm), trifluoroacetic acid (TFA) 99% 
spectrophotometric grade (Aldrich; Milwaukee, USA), formic acid (FA) 98-100% 
pro analysis (Merck; Darmstadt, Germany) were used for reagent preparation. A 
peptide stock solution [peptide, concentration in mmol/L; VYV, 0.29; YGGFL 
(leucine enkephalin), 0.20; DRVYIHFP (angiotensin II), 0.10; YPFPGPI (β-
casomorphin 7), 0.16; YPFPG (β-casomorphin 5), 0.21; GYPPT (gluten exorphin 
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A5), 0.19; YGGWL (gluten exorphin B5), 0.20] was used to evaluate the 
repeatability of the analytical LC-MS system. The first five peptides were obtained 
from Sigma (Zwijndrecht, The Netherlands) and the latter two from PepScan 
(Lelystad, The Netherlands). 
2.3. Sample Preparation 
Urine samples were thawed resulting in a minimum of 1 and maximum of 3 freeze-
thaw cycles, then they were mixed, acidified with 1% TFA, stored overnight on 
melting ice, and centrifuged to remove precipitate (10 min at 1500 g and 4 °C). The 
supernatant was diluted 1:1 with 0.2% FA in 10% ACN and stored at 4 °C until 
analysis. 
 Urinary creatinine concentrations were assayed on a Merck MEGA (Merck, 
Darmstadt, Germany) and on a Roche/Hitachi Modular P (Roche Diagnostics, Basel, 
Switzerland) analyzer using the alkaline picrate (Jaffe) and enzymatic creatinine 
(creatinine plus) assay, respectively. Urinary levels of β-hCG were measured on an 
AutoDELFIA (Wallac Oy, Germany) with a solid-phase, two-site 
fluoroimmunometric assay. 
2.4. Reversed Phase LC-MS analysis 
The injection order of the urine samples was randomized. Five μL of the 500-times 
diluted peptide stock solution (in 0.1% FA and 5% ACN) were injected onto the 
precolumn prior to injection of each urine sample. Between each injection the 
injection system was cleaned by rinsing with 70% ACN and filled again with 0.1% 
FA in 5% ACN. System stability was monitored and evaluated by 5 μL injections of 
the 500-times diluted peptide stock solution before and after each series of 10 urine 
samples. An equivalent of each urine sample corresponding to 50 nmol creatinine 
was injected in a first instance (creatinine-batch). In second instance, we calculated 
a median AUC214 and normalized all AUC214-based injection volumes to this value 
(AUC214-batch). The AUC214 was calculated between 20 and 80 min retention time, 
which corresponds to 4 - 64 min for mass spectrometric data acquisition (MS data 
acquisition was started 16 min later than the gradient program). The majority of 
UV-absorbing compounds eluted in between 20 and 80 min retention times [33]. 
 All LC-MS analyses were performed on an 1100 series capillary HPLC system 
equipped with a cooled autosampler (4 °C), a UV detector (λ=214 nm) and an SL Ion 
Trap mass spectrometer (Agilent Technologies). A urine volume equivalent to 50 
nmol of creatinine or the median AUC214 was desalted on an AtlantisTM dC18 
precolumn (2.1 × 20 mm, 3 μm particles and 10 nm pore diameter; Waters, Milford, 
Massachusetts, USA) using 0.1% FA in 5% ACN at a flow rate of 50 μL/min for 16 
min. Urinary compounds were back-flushed from the precolumn onto a 
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thermostated (25 °C) AtlantisTM dC18 analytical column (1.0 × 150 mm, 3 μm 
particles, 30 nm pores; Waters) and separated in 90 minutes at a flow rate of 50 
μL/min during which the percentage of solvent B (0.1% FA in ACN) in solvent A 
(0.1% FA in ultra pure H2O) was increased from 5.0 to 43.6% (0.43%/min). During 
these 90 minutes UV absorption and positive mode ESI-MS spectra were acquired. 
Settings for ESI and MS were as follows: 16.0 psi N2; drying gas: 6.0 L/min N2; T: 
325 °C; cap. voltage: 3.8 kV; skimmer: 57.5 V; cap. exit: 190.7 V; oct. 1: 4.12 V; oct. 
2: 2.49 V; oct. RF: 190.7 V; lens 1: -4.9 V; lens 2: -37.7 V; trap drive: 52.5; scan 
speed: 5500 m/z s-1; trap loading: 50 ms accumulation time or 30000 ions; scan 
range: 100-1500 m/z; Gaussian acquisition filter (width 0.1 m/z) of each scan; 
rolling average of 5 spectra. Spectra were saved in the centroid/line mode. 
Following each gradient, both columns were washed with 95% B for 5 min and 
equilibrated with 5% B for at least 10 min prior to the next injection. 
2.5. Data processing and analysis 
2.5.1. Data analysis for method evaluation 
LC-MS chromatographic data were analyzed with the Data Analysis software 
provided with the LC/MSD Trap (version 3.4 build 181) (Bruker Daltoniks, Bremen, 
Germany). For raw (unprocessed) LC-MS data, peak areas, intensities and retention 
times were obtained from the respective smoothed and baseline subtracted 
extracted ion chromatograms (EIC). One cycle of smoothing with a Gaussian filter 
at a width of 1 sec (± 1.8 points) preceded baseline subtraction with a flatness of 1. 
 Univariate statistical analyses were performed with the Statistical Product and 
Service Solutions package version 14.0 (SPSS Inc., Chicago, IL, USA). 
2.5.2. Data processing 
For processing and multivariate statistical analysis the original Bruker Daltoniks 
line-mode LC-MS data files were converted into ASCII-format with the Bruker 
Data Analysis software using an in-house developed visual basic script. The data 
processing workflow was developed and compiled using Visual Studio 2005, version 
8.0.50727.762 (SP.050727-7600, Microsoft Corp, Redmond, WA, USA). For further 
data analysis Matlab [version 7.3.0.267 (R2006b) Mathworks, Natick, MA, USA] 
and the PLS toolbox (version 4.0, Eigenvector Research Inc., Wenatchee, WA, 
USA) were used. 
 Initially the m/z ratios were meshed using a 2-dimensional (2D) Gaussian filter 
with sigma values of 0.05 min and 0.25 amu for the retention time and m/z 
dimension, respectively. Meshing partially compensated for the slight shift in m/z 
values as a result of trap overfilling that occurred during elution of abundant 
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compounds [39] and was used to smooth and fit deficient line data into a regular 
grid. Peak picking was performed using a geometrical algorithm based on local 
slope. The algorithm scans the mesh for local maxima. Starting at and descending 
from the peak maximum the algorithm then detected changes in the slope (from 
negative to positive) of the path of connected points thereby assigning the 
end/border of the peak. Connected points for one maximum were then considered 
to belong to one peak and the connected points in the perimeter of the peak were 
determined. This algorithm enabled the separation of overlapping peaks in 
particular shoulder peaks. After the algorithm has completed for a mesh, all peaks 
are output along with their height, width, volume, and extents in both m/z and 
retention time. Furthermore, each peak has a local estimate of the background 
value. In this work, the peak height was used for all analysis. Figure 1 shows a 










Example of a bird’s view (3-dimensional plot) of typical LC-MS data after data processing. Data were 
processed using 2-dimensional meshing without data reduction and peak picking using a geometrical 
algorithm based on local slope. 
 
After having defined all peaks accurately, time alignment was performed using 2D 
correlation optimized warping (COW) of peak locations stored in the peak list of 
each chromatogram [40]. Then the full set of peaks from all samples was searched 
for local clusters of peaks, referred to as “MetaPeaks.” The generated final peak 
matrix of the complete study consisted of an index(row)-sample(column)-
height(value) matrix. The index corresponds to one unique combination of a 
retention time and m/z value from a particular metapeak. This final peak matrix 
was used for multivariate statistical analysis by NSC and PCA. 
 All data processing was done on a personal computer equipped with a +3800 
MHz AMD processor with 4 GB of RAM. 
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2.5.3. Classification and multivariate statistical methods  
To select the most discriminating peaks, we applied the NSC classification 
algorithm [37;41]. NSC regularizes data whereby class-specific centroids are 
“shrunk” toward the overall (nonclass-specific) centroid, which has the effect of 
eliminating the influence of the most weakly correlated peaks, thereby reducing 
the capacity to overfit [42]. This algorithm is used to select peaks that are relevant 
for the discrimination of the predefined classes in conjunction with permutation 
tests to validate the classification algorithm [43] using leave-one-out cross-
validation (LOOCV) to avoid overfitting due to single outliers. The optimal 
shrinkage value was the value at which LOOCV showed the lowest classification 
error. In LOOCV one observation per class is iteratively omitted from the data set 
that is used to construct the classification model, which is then used to classify the 
omitted observation as case or control (e.g. pregnant or non-pregnant in this study). 
Variables selected at the highest shrinkage value (lowest number of peaks) and 
lowest LOOCV error, were employed for construction of the final classification 
model. The selected peaks were then analyzed and visualized by plotting the first 
two principal components obtained after PCA [38]. As a measure for class 
separation the Mahalanobis distance (MD) was calculated [44]. We consider an MD 
above 4.0, corresponding to a difference of 4 sigma between the mean centroids of 
the classes [43], as indicative for significant class separation. 
3. Results 
3.1. Evaluation of the normalization strategy and LC-MS system 
In pregnant females the urine volume equivalent to 50 nmol creatinine 
corresponded to a higher mean (±SD) of the AUC of the total chromatogram (TIC) 
between 20 and 105 min retention time than in non-pregnant female controls: 5.4 
(±0.8) *109 arbitrary units (AU) vs. 4.7 (±0.6) *109 AU, respectively (p<0.001). There 
was no significant difference (p>0.2) between the median (range) AUCTIC of the 
creatinine- (4.9 (3.7-7.4) *109 AU ) and the AUC214-normalized (4.7 AU (3.2-8.1) 
*109 AU) batches. The RSD of the AUCTIC was lower for the AUC214-normalized 
data than for creatinine-normalized data, 15 vs. 24%, respectively. Figure 2 shows 
histograms of the RSD for all peak intensities in the final peak matrix of the 
creatinine- and AUC214-normalized data. The AUC214-normalized LC-MS data 
(11639 peaks; median RSD 96.0%) had a higher (p<0.001) median RSD of peak 
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Histogram of the relative standard deviation (RSD) of peaks in the final peak matrix from the batch that was 
normalized to creatinine (a urine volume corresponding to 50 nmol creatinine was injected; 12233 peaks; 
filled line) and the batch that was normalized to the area under the curve at 214 nm between 20 and 80 min 
retention time (AUC214; 11639 peaks; striped line). Each batch consisted of urine samples from 25 pregnant 
females and from 25 apparently healthy non-pregnant females. 
 
Normalization to creatinine (median RSD 88.7%) better reduced the variation in 
the pregnant group (p<0.001) than normalization to AUC214 (median RSD 92.3%). 
Also in the non-pregnant group, normalization to creatinine (median RSD 90.1%) 
better reduced the variation (p<0.001) than normalization to AUC214 (median RSD 
95.3%). Normalization of the injection volume to the AUC214 better reduced the 
RSD of the AUCTIC compared to normalization to the creatinine concentration. 
Remarkably, creatinine-normalization resulted in a lower median RSD of peak 
heights in each group (pregnant/non-pregnant) than AUC214-normalization. 
 System-stability was evaluated by calculating the within-series correlation of 
six 5 μL injections of the 500-times in 0.1% FA and 5% ACN diluted peptide stock 
solution (IS) before and after each series of 10 urine samples. Figure 3 shows a high 
correlation (R2 > 0.95) of peak intensities for creatinine-normalized samples as well 
as for AUC214-normalized samples (R2 > 0.9), between the six individual samples, 
except for the first file in the creatinine-batch (absence of peak for peptide VYV 
from the peak list) and the last file in the AUC214-batch (absence of peak for peptide 
YGGWL from the peak list). The latter finding is remarkable, because the peak is 
clearly visible in the raw LC-MS data, which suggests a data processing error. This 
reasoning is not valid for the missing VYV peak, because the raw MS data lacks this 
peak at the expected retention time. 
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Figure 3 
Correlation map of the final peak matrix (obtained as described in ‘Experimental’) from six 5 μL injections of 
500-fold diluted peptide stock solution (1.0-2.9 pmol injected). These samples were analyzed before and after 
each series of 10 samples (equivalent to ±24h of analysis time) of the creatinine-normalized batch (A) and the 
batch of samples that was normalized to the area under the curve at 214 nm (B). Samples are regrouped by 
similarity. The numbers correspond to the order of analysis (e.g. 23 means that this sample was the 23rd 
sample that was analyzed in this batch. 
 
3.2. Data processing and multivariate statistical analysis of LC-
MS profiles 
3.2.1. Data processing and analysis 
The data processing workflow was significantly improved in comparison to our 
previous report (33). The previous workflow included binning from an 
instrumental resolution of 0.1 amu to 1 amu. This was done to reduce the size of the 
datasets (approximately by a factor 10) to reach an acceptable data processing and 
analysis time with Matlab on a desktop computer (see ‘Experimental’ for 
specifications). The new data processing workflow (C++) compared to the old data 
analysis processing ((33); Matlab) is improved by the following: (i) C++ provides 
much greater performance, particularly with large spectral datasets. (ii) Data 
meshing is used to address the problem of the irregular distribution of peak 
intensities of line data, and to detect peaks by assigning the top of a peak. (iii) 
Higher performance when working with regular, meshed data rather than irregular 
points. (iv) Calculation of peak parameters (height, volume, extent, background) 
along with the separation of overlapping peaks. (v) Finally, the peak picking 
algorithm is better capable of detecting and accurately quantifying relatively small 
peaks (low S/N), thus enlarging the dynamic range. 
 The most important improvement is, however, the inclusion of 2D alignment 
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retention time was ≤0.52 min (33). Comparing peak heights of batches (e.g. a 
training-set and a test-set) that are analyzed interspaced in time (e.g. months to 
years between analyses) requires proper peak matching in both the time- and m/z-
dimension. First, COW (42) was applied to align the TIC of different samples. COW 
is suitable for single signal detectors (e.g. UV, fluorescence, flame-ionization etc.) 
and for samples that contain low numbers of peaks. We adapted the COW 
algorithm to calculate the correlation between the TIC (hereafter referred to as the 
‘COW-TIC’) of different samples in a similar manner as for single signal detectors. 
However, urine is a complex biological sample and its composition is highly 
variable, qualitatively and quantitatively. The biological variance of the 
concentration of individual compounds is high, resulting in markedly different TIC 
of samples from different individuals. Therefore, the COW-TIC algorithm, a 1-
dimensional alignment algorithm, was not able to align the 50 chromatograms, 
because retention time shifts within-batch and biological variation led to dissimilar 
TIC. 
 The time alignment algorithm was then changed to calculate correlations 
based on the peak list of each chromatogram. By doing this, 2 dimensions (2D: 
retention time and the mean m/z-value of the intensity distribution, including the 
measured widths of each peak in m/z and retention time) are taken into account in 
contrast to the COW-TIC, that uses only 1 dimension (1D; the TIC is a summed 
intensity) for COW. The new 2D-alignment algorithm corrects for large time shifts. 
In addition, inclusion of peak matching using metapeak clusters, and 
implementation of a 2D ‘shift-area’ to compensate for shifts in retention time and 
m/z decreases the probability of peak mismatching compared to the 1D sliding 
windows peak matching algorithm used previously (33). In summary the new data 
processing workflow resulted in a well-aligned peak matrix with a more accurate 
measure for peak intensity – all with significantly improved performance. 
 To evaluate whether data processing reduced the variation in retention time 
between the different chromatograms, the TIC was divided into 10 segments of 8 
min between 25 and 105 min retention time. This is the region where the majority 
of peaks detected by MS elute (see example of TIC in (33)). From each of these 
segments, the four highest peaks were extracted from the final peak matrix of the 
AUC214-batch. From these four highest peaks, the extracted ion chromatogram 
(EIC) of the peak with the ‘poorest’ alignment before and after 2D-alignment is 
depicted in Figure 4. 
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Each panel represents an extracted ion chromatogram (EIC) of the peak with the ‘poorest’ time alignment 
derived from the four highest peaks in each of the ten 8 minute segments between 25 and 105 minutes 
retention time. The upper trace in each panel represents meshed LC-MS data before 2-dimensional (2D: 
retention time and m/z) alignment using correlation-optimized warping, while the lower trace represents 
meshed data after 2D-alignment. The final peak matrix from the analysis 50 urine samples (25 pregnant 
females; 25 non-pregnant females) that were normalized to the area under the curve at 214 nm was used. 
 
3.2.2. Multivariate statistical comparison of urine from pregnant and 
non-pregnant females 
The final peak matrix of the AUC214-batch contained 15876 peaks. By varying the 
shrinkage value of the NSC classifier and following the LOOCV error, we obtained 
a region with zero cross-validation error (Figure 5A). The plot of all 15786 peaks in 
the final peak matrix explains only 11.5% of the variance on principal component 
(PC) 1 and PC 2 (Figure 5B), although there was little overlap between the 
pregnant and non-pregnant groups (MD of 2.45). This resulted in a sensitivity of 
96% and a specificity of 100% when using all peaks in the peak matrix for sample 
classification. 
 The NSC algorithm selected 186/15876 (1.2%) peaks at a shrinkage of 3.11 that 
separated (MD is 5.39) the two classes without any LOOCV error (specificity and 
sensitivity of 100%) (Figure 5A and 5C). Using these 186 discriminatory peaks, PC 1 
and PC 2 explain 52.1% of the variance in the data (Figure 5C). Increasing the 
shrinkage to 7.52 resulted in the selection of 10/15876 (0.063%) discriminatory 
peaks that explained 90.6% of the variance in the data through PC 1 and PC 2 
(Figure 6A). The MD was 4.16, which indicates significant separation of the classes, 
with a sensitivity of 96% and specificity of 100%. Figure 6B shows the individual 
values in a Box-Whisker plot for the only peak (514.6 m/z, 95.65 min; p=6.8*10-10) 
that remains at a shrinkage value of 12.55 (92% sensitivity, 100% specificity). 
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Leave-one-out cross validation (LOOCV) error plot (panel A) of the classification model derived from the 
analysis of the final peak matrix (15876 peaks) from data of 50 urine samples (25 pregnant females; 25 non-
pregnant females) that were normalized to the area under the curve at 214 nm. Cross-validation error (Y) was 
calculated at each shrinkage value (X) using the nearest shrunken centroid algorithm. The inserted table 
reports the number of discriminatory peaks, sensitivity and specificity of the classification model at three 
shrinkage values. Plot of principal component (PC) 1 and PC 2 using all peaks (15876) in the final peak matrix 
(panel B). Plot of PC 1 and PC 2 using 186/15876 peaks (1.2%) that were selected by the nearest shrunken 
centroid (NSC) algorithm at a shrinkage value of 3.11 (panel C). Pregnant females (T), non-pregnant females 
(z), discriminatory peaks (Ä). 
 
 
We used the list of 186 discriminatory peaks that was obtained at a shrinkage value 
of 3.11 (sensitivity 100%, specificity 100%) as starting point to select biomarker 
candidates. A histogram of the 10log of the p-values from the non-parametric 
comparison (Mann-Whitney U test; MWU-test) of discriminatory peak heights in 
the final peak matrix between pregnant and non-pregnant females is depicted in 
Figure 7. All selected peaks had p-values < 0.01 with some p-values reaching down 
to 10-10. One selected peak had a p-value of 0.4 and was, according to the MWU-
test, not significantly different between pregnant and non-pregnant females. This 
peak was probably selected because it is a Na+-adduct (81.25 min, 722.7 m/z) of a 
highly discriminatory peak (81.26 min, 700.6 m/z; p= 3.17*10-07). 
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Plot of principal component (PC) 1 and PC 2 using 10/15876 peaks (0.063%) that were selected by the nearest 
shrunken centroid (NSC) algorithm at a shrinkage value of 7.52 from the final peak matrix (15876 peaks) from 
data of 50 urine samples (25 pregnant females; 25 non-pregnant females) that were normalized to the area 
under the curve at 214 nm (panel A). Box-and-Whisker plot (panel B) of the only peak (514.6 m/z; 96.7 min) 
that was selected by the nearest shrunken centroid algorithm at a shrinkage value of 12.55 (p-value = 6.18 × 
10-10; see Table 1). Pregnant females (T), non-pregnant females (z), discriminatory peaks (Ä). 
 
 
In addition, the use of a non-parametric test like the MWU-test, which compares 
mean ranks, may be less appropriate when many values in both groups are set at 0 
(equal ranks). Visual inspection of both the raw and processed data show a clear 
difference in peak height of this peak, and a Student’s t-test of the non-Gaussian 
distributed data resulted in p=3.95*10-4. Interestingly, in the urine of pregnant 
females we found 12/186 (6.5%) discriminatory peaks to correlate (p<0.05; 5 
negatively, 7 positively) with free β-hCG subunit levels. The free β-hCG 
concentration in the urine samples of pregnant females ranged between 0.12 and 
2.8 μmol/L, which would be equivalent to 0.36 to 17 pmol on-column, based on the 
conversion table of the WHO of 1975 (1 IU = 0.045 nmol free β-hCG). The β-hCG 
subunit, however, was not identified by LC-MS/MS (unpublished observation). 
 Redundancy in the peak list was explored and reduced by manual deisotoping 
and charge-state deconvolution. Plotting the raw m/z values against retention time 
revealed furthermore Na+ adducts and H2O-loss due to “in-source” fragmentation of 
certain discriminatory peaks. Correlation analysis of the intensity of discriminatory 
peaks showed that some are quantitatively related (unpublished observations), 
implying structural or functional similarities. The curated peak list contained 
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Figure 7. 
Histogram of the 10log plot of p-values obtained 
by non-parametric comparison of the peak-
volumes of 186 peaks that discriminate urine of 
25 pregnant females from urine of 25 non-
pregnant females with 100% sensitivity and 100% 
specificity. One peak was not statistically 










Ten of these 38 peaks were the principal discriminatory peaks at a shrinkage level 
of 7.52 (sensitivity 96%, specificity 100%) (Table 1). Univariate statistical 
comparison (Table 1) and EIC (Figure 8) of these discriminatory peaks revealed 
strongly elevated levels in the majority of the urine samples from pregnant females 
making them candidate biomarkers for pregnancy. 
 
Table 1. Characteristics of 10 peaks that discriminate between urine samples from 
pregnant and non-pregnant females at a shrinkage value of 7.52 (sensitivity 
96%, specificity 100%). 
 
Peak # RT a m/z b Peak height pregnancy (P) c Peak height controls (NP) d p-value e 
 (min) (M+1H)1+ Arbitrary units Arbitrary units  
1 78.3 604.6 1390000 (0-3100000) 34549 (0-192143) 1,79E-008 
2 95.6 285.4 1140000 (353106-2730000) 0 (0-324000) 3,68E-010 
3 95.6 1015.9f 903843 (0-2220000) 7364 (0-246307) 2,24E-007 
4 95.7 203.4 44150 (14448-95888) 3996 (0-17652) 1,35E-009 
5 95.7 514.6 719223 (216616-1410000) 0 (0-213025) 6,18E-010 
6 95.7 519.7 432093 (0-533025) 64568 (0-259183) 2,29E-008 
7 97.0 519.7 180159 (0-347504) 8948 (0-35279) 1,79E-007 
8 98.3 301.6 223725 (0-392491) 4459 (0-35978) 6,42E-006 
9 98.3 477.7 221690 (0-379820) 7231 (0-52876) 2,23E-006 
10 98.3 517.6 246524 (91532-559978) 9057 (0-78090) 1,23E-009 
 
Data represent median values (minimum-maximum). Figure 8 depicts the extracted ion chromatograms of the 
discriminatory peaks. a RT, retention time; b Mass-to-charge ratio derived from final peak matrix generated as 
described under ‘Experimental’; c Peak height derived from the final peak matrix of AUC214-normalized LC-
MS data of 25 pregnant females (P); d Peak height derived from the final peak matrix of AUC214-normalized 
LC-MS data of 25 female controls (C); e p-value derived from Mann-Whitney U tests for non-Gaussian 
distributed data (tested with the Shapiro-Wilk test and normality plots); f z=2. 
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Overlaid extracted ion chromatograms (EIC) of 10 peaks that discriminate between urine samples from 
pregnant and non-pregnant females with a sensitivity of 96% and specificity of 100%. The upper panel shows 
EICs of peaks from 25 pregnant females. The lower panel shows EICs of peaks from 25 non-pregnant females. 
The data is derived from the final peak matrix of the AUC214-normalized batch. Table 1 reports the 
characteristics of the discriminatory peaks. In most panels additional peaks are present with similar m/z-
values but different retention times than the discriminatory peaks (centered peak in each panel). These 
additional peaks also differentiate between the samples of pregnant and non-pregnant females. More than 
95% of these additional peaks have discriminatory properties (included in list of 186 discriminatory peaks at a 
shrinkage of 3.11), but they are not selected at the shrinkage level of 7.52. 
 
4. Discussion and conclusion 
The aim of this work was to evaluate our comparative urine analysis platform for its 
potential to differentiate between two physiological states. For this we have used 
profiling of LMW urinary compounds from pregnant and non-pregnant females by 
LC-MS and subsequent multivariate statistical analysis of processed data. 
 Normalization of the injected amount to the AUC214 did not result in a 
lowering of the peak height variance compared to normalization of creatinine, 
although this did reduce the variance in the AUCTIC. This suggests that biological 
variation is not compromised by normalization to the AUC214. Moreover, AUC214-
normalization better normalizes the injected amount if the AUCTIC is considered to 
be representative for this. It should, however, be remarked that the peaks in the 
peak matrix of the AUC214-batch were not matched to those of the creatinine-batch. 
An alternative, and even better approach is to run quality control (QC) samples 
(e.g. a pooled urine sample) before and after a predefined number of samples (e.g. 
10). These QC could be analyzed at different creatinine concentrations (e.g. 25, 50 
and 75 nmol creatinine) to evaluate the biological and analytical variation of the 
method and its quantitative properties. Furthermore, it can be questioned whether 
normalization to the AUC214 is appropriate in case of renal dysfunction. Large 
amounts of UV-absorbing compounds are excreted during renal pathology which 
will then lead to erroneous normalization if compared to urine samples from 
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controls with normal renal function. Thus, in each biomarker discovery study for 
disorders of the genitourinary tract the normalization strategy should be dependent 
on the disease under study. 
 Our new data processing workflow improved the quality of the final peak 
matrix with respect to the comparability and accuracy. Respectively, this was done 
by geometrical peak picking and peak measurement, and COW in 2D (retention 
time and m/z). In addition, full-resolution Ion-Trap MS data was used instead of 
binned Ion-Trap MS data to avoid loss of information during data processing. 
However, some peaks were not properly aligned (Figure 3) and peaks with low S/N 
were not properly picked and thus not included in the peak matrix. Adaptation of 
certain settings, e.g. 2D peak detection window, 2D alignment algorithm window, 
to the quality of the data is needed to optimize the output of the algorithms. 
 By assessing the relation between shrinkage value, cross-validation error, 
sensitivity, specificity and the number of discriminatory peaks we were able to 
optimize and improve the selection of discriminatory peaks, notably by reduction 
of the number of candidate biomarkers. Manual univariate comparison and 
visualization of selected peaks for both classes aided also in biomarker selection. In 
addition, we observed that the model at a shrinkage value of 3.11 (186 peaks) with 
both a specificity and sensitivity of 100% contained many ‘noisy’ and redundant 
peaks which might be caused by the narrow window that was used to match peaks 
to the metapeaks. The trade-off between a decrease in sensitivity and an increase in 
number of discriminatory peaks, might be a good strategy for selecting ‘real’ 
candidate biomarkers that are characterized by a strong discriminatory capacity. 
Implementing sensitivity, specificity and MD as measures for proper sample 
classification should improve the statistical evaluation and thus the quality of the 
selected biomarker candidates. The next step is to test the performance of the final 
classification model and the associated candidate biomarkers in larger independent 
test sets that include related ‘disorders’ such as extra-uterine pregnancies and testis 
carcinoma. We will also investigate the effects of short- and long-term storage (-20 
°C) of urine samples from pregnant and non-pregnant females on the classification. 
However, the aim of this study was not to find a biomarker for pregnancy, but 
merely to obtain an advanced-proof-of principle and to optimize the comparative 
analysis platform. 
 
At present we are trying to identify the discriminatory peaks by LC-MS/MS. The 
majority of the discriminatory peaks (independent of the shrinkage value) eluted 
late in the gradient, which suggests that they are rather hydrophobic. In addition, 
the low molecular masses of the discriminatory peaks and their non-peptide like 
fragmentation in MS/MS experiments (unpublished observations) suggests that we 
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are dealing with metabolites of pregnancy-related hormones and possibly post-
translationally modified proteins (e.g. glycoproteins). The anticipated variation in 
the concentration of these discriminatory peaks because of the large variation in 
gestational age, is clearly exemplified by the larger distribution of the samples in 
the ‘pregnancy’ cluster compared to the ‘non-pregnant’ cluster (Figure 6A). 
 Pregnancy is a physiological condition in which modified immune responses 
allow a semi-allogenic fetus to survive within the uterine environment. The 
gestational tissues, including the uterine myometrium, the decidua, the placenta 
and fetal membranes, allow the fetus to survive and considerably modify the 
composition of blood, urine, amniotic fluid, cervicovaginal fluid etc. during 
gestation [45]. These biofuids are increasingly investigated for early diagnostic 
markers of preterm labor, pre-eclampsia and fetal growth restriction [46-48]. 
Compounds that are differentially expressed in pregnancy and of which some are 
even pregnancy specific are placental lactogen, chorionic gonadotropin (of which β-
hCG is a subunit), fetal fibronectin, α-fetoprotein, dimeric inhibin A, unconjugated 
estriol, placental peptides, pregnancy-associated placental protein-A [3]. In our 
group of pregnant females the gestation duration ranged from 7.6-15.7 weeks, 
which leads to a considerable variation in the concentrations of these pregnancy 
specific compounds in blood. This concentration variation of hormones, proteins, 
their proteolytic fragments or conjugates is probably reflected in the composition of 
urine. Comparing the urinary composition of pregnant with non-pregnant females 
we expected on forehand to find clear differences, because the analytical method 
(reversed phase LC – positive mode MS) is capable of detecting those compounds. 
 The finding of correlations between β-hCG in urine and peak heights of 
certain discriminatory peaks in the urine of pregnant females suggests that some of 
the selected peaks discriminate patients based on an indirect relationship, either 
metabolic, functional or structural, with the total content of free β-hCG in urine. 
However, some correlations may be false because of a type-II error. The sample 
pretreatment procedure that consisted of at least 1 freeze-thaw cycle and sample 
acidification for mild protein precipitation could have removed pregnancy-related 
proteins or their fragments. Also, most pregnancy-related proteins are 
glycoproteins, which may have hampered the identification of these proteins by 
‘routine’ proteomics, i.e. analysis by LC-MS/MS and protein database queries. 
 
In summary the comparative urine analysis method has benefited from 
improvements in the data processing workflow. It was possible to discriminate 
urine samples of pregnant females from those of non-pregnant females with a 
sensitivity of 96% and specificity of 100% using only 10 discriminatory peaks. 
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Identification of the discriminatory peaks and validation of the classification model 
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